On Friday, Akero Therapeutics Inc (NASDAQ: AKRO) opened higher 4.90% from the last session, before settling in for the closing price of $31.20. Price fluctuations for AKRO have ranged from $15.32 to $37.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -34.94% at the time writing. With a float of $58.43 million, this company’s outstanding shares have now reached $69.80 million.
Let’s look at the performance matrix of the company that is accounted for 56 employees. In terms of profitability, gross margin is 98.59%, operating margin of -94813.73%, and the pretax margin is -83528.87%.
Akero Therapeutics Inc (AKRO) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Akero Therapeutics Inc is 16.29%, while institutional ownership is 96.75%. The most recent insider transaction that took place on Nov 15 ’24, was worth 251,274. In this transaction Chief Development Officer of this company sold 9,061 shares at a rate of $27.73, taking the stock ownership to the 74,158 shares. Before that another transaction happened on Nov 06 ’24, when Company’s Chief Development Officer sold 10,000 for $35.19, making the entire transaction worth $351,890. This insider now owns 74,158 shares in total.
Akero Therapeutics Inc (AKRO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -34.94% per share during the next fiscal year.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Check out the current performance indicators for Akero Therapeutics Inc (AKRO). In the past quarter, the stock posted a quick ratio of 17.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -1.16 in the next quarter and is forecasted to reach -4.74 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Akero Therapeutics Inc (NASDAQ: AKRO) saw its 5-day average volume 0.78 million, a negative change from its year-to-date volume of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 57.27%. Additionally, its Average True Range was 1.79.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 78.83%, which indicates a significant increase from 64.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.47% in the past 14 days, which was higher than the 49.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.95, while its 200-day Moving Average is $25.41. Nevertheless, the first resistance level for the watch stands at $33.44 in the near term. At $34.15, the stock is likely to face the second major resistance level. The third major resistance level sits at $35.34. If the price goes on to break the first support level at $31.53, it is likely to go to the next support level at $30.34. The third support level lies at $29.63 if the price breaches the second support level.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
There are currently 69,799K shares outstanding in the company with a market cap of 2.40 billion. Presently, the company’s annual sales total 0 K according to its annual income of -151,760 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -72,710 K.
